Journal
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
Volume 61, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jddst.2021.102333
Keywords
Travoprost; Penetration enhancer; In situ gelling; Liposomes; Mucoadhesive polymers
Categories
Ask authors/readers for more resources
Travoprost (TRAVO) is a prostaglandin analog used to reduce intraocular pressure in patients with glaucoma and ocular hypertension. This study successfully developed a novel in situ mucoadhesive ocular liposomal gel to enhance the therapeutic efficacy of TRAVO. The selected liposomal formulation showed high drug entrapment efficiency, suitable vesicle size, polydispersibility, and zeta potential, and was further incorporated into an in situ mucoadhesive gel with controlled release and improved bioavailability.
Travoprost (TRAVO) is a prostaglandin analog used to reduce the intraocular pressure (IOP) for patients suffering from glaucoma and ocular hypertension. The aim of the present study was the development of a novel in situ mucoadhesive ocular liposomal gel to prolong and improve therapeutic efficacy of TRAVO. With this purpose, liposomal formulations were prepared by implementing a full factorial design to study the effect of three factors; type of permeation enhancer (PE), PE concentration and the ratio of lecithin: cholesterol at two levels. The evaluated responses were entrapment efficiency (EE), vesicle size (VS), polydispersibility (PDI) and zeta potential (ZP). L-6 (selected liposomal formulation), composed of 20% sodium deoxycholate (Na DOC) and lecithin: cholesterol at 4:1 ratio showed high EE (67.55%), suitable Ps and PDI (74.19 nm and 0.433) and ZP (-75.5 mv). L 6 was incorporated in a second 3(1) x 2(1) design to study the effect of concentration of gellan gum (at three level) and carbopol 934 (at two levels) to develop in situ mucoadhesive gel. Selected liposomal in situ gel LISG(2) (0.25% gellan gum and 0.5% carbopol 934), showed minimum release (18.2%) after 30 min and maximum release after 24 h (72.5%) and achieve maximum viscosity (4445cps) at physiological conditions, mucoadhesive force (0.438 N), with minimum viscosity (124 cps) at normal conditions. Selected LISG(2) will be further in vivo evaluated for irritation and pharmacokinetic. TRAVO LISG was non irritant and showed improved bioavailability (higher concentration of TRAVO in aqueous humor) when compared to the marketed product, and showed more prolonged effect compared to liposomal formulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available